Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04395066 |
Recruitment Status :
Not yet recruiting
First Posted : May 20, 2020
Last Update Posted : May 20, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Severe Pneumonia Immunosuppressed Hosts Diagnosis | Diagnostic Test: CD55 |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 171 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 28 Days |
Official Title: | Molecular Diagnosis and Prognosis of Severe Pulmonary Infection in Immunosuppressed Hosts |
Estimated Study Start Date : | June 1, 2020 |
Estimated Primary Completion Date : | June 1, 2023 |
Estimated Study Completion Date : | June 1, 2023 |
- Diagnostic Test: CD55
CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
- Number of patient diagnosed with severe pneumonia within 28 days [ Time Frame: 28 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
① Age ≥ 18 years, ≤ 75 years, male or female
-
Patients diagnosed with severe pneumonia ③ Immunosuppressed patients
- Patient informed consent
-
Exclusion Criteria:
-
① Pregnant women, lactating women and women who are at risk of pregnancy.
-
Patients with malignant neoplasms that have metastasized extensively and are expected to have a short survival period.
-
Patients with obstructive pneumonia and interstitial fibrosis due to lung tumours.
-
refusal of the patient or the patient's family to participate in the study.
- Refusal of invasive mechanical ventilation and tracheal intubation by the patient or the patient's family.
-
-
-
Responsible Party: | Ruilan Wang, PhD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
ClinicalTrials.gov Identifier: | NCT04395066 |
Other Study ID Numbers: |
2018KY149 |
First Posted: | May 20, 2020 Key Record Dates |
Last Update Posted: | May 20, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Pneumonia Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |